These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 28741691)

  • 1. Earlier initiation of transfusional and iron chelation therapies in recently born children with transfusion-dependent thalassemia.
    Origa R; Tatti F; Zappu A; Leoni GB; Dessì C; Moi P; Morittu M; Orecchia V; Denotti AR; Pilia MP; Anni F; Perra M; Casini MR; Barella S
    Am J Hematol; 2017 Nov; 92(11):E627-E628. PubMed ID: 28741691
    [No Abstract]   [Full Text] [Related]  

  • 2. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
    Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serum ferritin in the follow-up of homozygotic beta-thalassemia treated with blood transfusion and iron-chelating agents].
    Esposito L; Ferrara M; Ponte G
    Pediatria (Napoli); 1981 Sep; 89(3):479-92. PubMed ID: 7346759
    [No Abstract]   [Full Text] [Related]  

  • 4. Survival in thalassemia with conventional treatment.
    Borgna-Pignatti C; Zurlo MG; DeStefano P; DiGregorio F; Di Palma A; Piga A; Melevendi C; Burattini MG; Terzoli S; Masera G
    Prog Clin Biol Res; 1989; 309():27-33. PubMed ID: 2675094
    [No Abstract]   [Full Text] [Related]  

  • 5. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose intravenous chelation therapy with deferoxamine.
    Cohen A; Mizanin J; Schwartz E
    Prog Clin Biol Res; 1989; 309():125-31. PubMed ID: 2780746
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Causes of hospital admission in children and adults with transfusion-dependent thalassemia in Sardinia, 2000-2015.
    Origa R; Anni F; Mereu L; Follesa I; Campus S; Dessì C; Foschini ML; Leoni G; Moi P; Morittu M; Orecchia V; Perra M; Zappu A; Podda RA
    Ann Hematol; 2017 Jun; 96(6):1041-1042. PubMed ID: 28280993
    [No Abstract]   [Full Text] [Related]  

  • 10. [Electrocardiographic and radiologic evaluation in cardiac involvement in patients with beta-thalassemia major].
    Lo Jacono F; Agnello D; Malizia R; Maltese I; Marasa' R
    Pediatria (Napoli); 1980 Sep; 88(3):385-93. PubMed ID: 7220158
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiac complications in homozygous beta-thalassemia.
    Wonke B; Hoffbrand AV; Aldouri MA; Ward SE
    Prog Clin Biol Res; 1989; 309():51-6. PubMed ID: 2780750
    [No Abstract]   [Full Text] [Related]  

  • 12. Toxicity of oral iron chelator L1.
    Bichile SK; Mehta PJ; Parekh SJ
    J Assoc Physicians India; 1993 Jun; 41(6):323-4. PubMed ID: 8005960
    [No Abstract]   [Full Text] [Related]  

  • 13. Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload.
    Puliyel M; Sposto R; Berdoukas VA; Hofstra TC; Nord A; Carson S; Wood J; Coates TD
    Am J Hematol; 2014 Apr; 89(4):391-4. PubMed ID: 24347294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current approach to iron chelation in children.
    Aydinok Y; Kattamis A; Viprakasit V
    Br J Haematol; 2014 Jun; 165(6):745-55. PubMed ID: 24646011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monitoring and appraisal of the effects of blood transfusion and iron chelation in thalassemia major].
    Girot R; Triadou P; Bories D; Jeannel F; Thevenin M; Rymer JC
    Nouv Rev Fr Hematol (1978); 1982; 24(5):281-7. PubMed ID: 7167380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive transfusion therapy in thalassemia major.
    Beard ME; Necheles TF; Allen DM
    Pediatrics; 1967 Nov; 40(5):911-5. PubMed ID: 6075668
    [No Abstract]   [Full Text] [Related]  

  • 17. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalassemia: the continued challenge.
    Nathan DG
    Ann N Y Acad Sci; 2005; 1054():1-10. PubMed ID: 16339645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S; Zarei T; Zahedi Z; Karimi M
    Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
    ElAlfy MS; Sari TT; Lee CL; Tricta F; El-Beshlawy A
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):601-5. PubMed ID: 20921906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.